openPR Logo
Press release

Pancreatic Cancer Therapeutics Market to Witness Significant Growth due to Increase in Number of Pancreatic Cancer Cases in the Coming Years | Top Key Players are Eli Lilly and Company, Novartis, Ipsen, Pfizer, Celgene, Astellas Pharma US, Spectrum Pharma

06-07-2019 12:29 PM CET | Health & Medicine

Press release from: Pharma Proff

Pancreatic cancer occurs when malignant cells develop in the part of pancreas, resulting in the formation of a tumor. Pancreatic cancer typically spreads rapidly to nearby organs. It is rarely detected in its early stages.
Diabetes is one of the major signs of pancreatic cancer, especially occurs with weight loss, jaundice or pain in the upper abdomen that spreads to the back. Jaundice, digestive problems, blood clots, and pancreatitis are some of the clinical symptoms of pancreatic cancer that help in diagnosing of patients in its early stage.

Download the sample report pages at: https://www.pharmaproff.com/request-sample/1236

According to the research findings, there are nine drugs approved in the market for the treatment of pancreatic cancer, and over 100 drugs are in pipeline, demonstrating positive clinical results against the disease. For instance, Napabucasin, an orally administered drug, currently in phase III stage of development, is being developed by Sumitomo Dainippon Pharma Co. Ltd., for the treatment of pancreatic cancer. The phase III result of Napabucasin, in patients with pancreatic cancer, showcased high response rate, of 78%, for the treatment of the disease. Also, prominent players, such as AstraZeneca plc, Sumitomo Dainippon Pharma Co. Ltd., and many others are also currently involved in the development of pancreatic cancer therapeutics.

Get the detailed analysis at: https://www.pharmaproff.com/report/pancreatic-cancer-therapeutics

Increasing prevalence of pancreatic cancer is playing a pivotal role in the growth of pancreatic cancer therapeutics market. The incident cases of pancreatic cancer in the 7 major markets (7MM) are expected to increase from 151,381 cases in 2016 to 179,629 by 2028. Growing geriatric population is one of the key risk factors for this disease. Changes in ethnicity, obesity, and diabetes are some other key risk factors for this disease. Increase in the disease incidence is expected to fuel the growth of the pancreatic cancer therapeutics market in the coming years.

Governments across the world have shown an increased interest for the treatment of life-threatening diseases, including pancreatic cancer. This has led to increased investments by the government bodies as well as pharmaceutical manufacturers for the development of new drugs. For instance, the U.S. government increased funding of $179.1 million for the National Cancer Institute in 2019 and additional funding of $215 million for the pancreatic cancer research. Thus, this increase in the R&D investments lead to the discovery of more drugs for the treatment of pancreatic cancer; thereby, fueling the growth of the pancreatic cancer therapeutics market.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1236

Novartis AG, Ipsen Pharma, Pfizer Inc., Celgene Corporation, Astellas Pharma, Spectrum Pharmaceuticals Inc., and Eli Lilly and Company are some of the companies involved in the commercialization of pancreatic cancer therapeutics.

The report comprises detailed market analysis of therapeutics being marketed for the treatment of pancreatic cancer. Comprehensive insights on the marketed products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the manufacturing and commercialization of pancreatic cancer therapeutics. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to pancreatic cancer.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Therapeutics Market to Witness Significant Growth due to Increase in Number of Pancreatic Cancer Cases in the Coming Years | Top Key Players are Eli Lilly and Company, Novartis, Ipsen, Pfizer, Celgene, Astellas Pharma US, Spectrum Pharma here

News-ID: 1767879 • Views: 402

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Pancreatic

Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: https://www.pharmaproff.com/request-sample/1024 Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Opportunity Analysis …
Exocrine pancreatic insufficiency (EPI) is a condition associated with deficiency of exocrine pancreatic enzymes that results in the inability to digest food or maldigestion. EPI may be associated with certain diseases and conditions that affect the pancreas such as cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and others. Chronic pancreatitis (CP) is the most common cause of EPI in adults that is followed by cystic fibrosis (CF). CF is an inherited
Pancreatic Cancer Pipeline Drugs Review H1 2017
Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,